Katherine S. Tweden

article

Clinical use of a 180‐day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes

Concetta Irace, Antonio Cutruzzolà, Annamaria Nuzzi, Roberta Assaloni, more

Diabetes, Obesity and Metabolism > 22 > 7 > 1056 - 1061

Aims This real‐world study evaluated the changes in glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics associated with use of the implantable 180‐day Eversense CGM System (Eversense) in patients with type 1 diabetes. Materials and methods This was a prospective, multicentre, observational study among adult participants aged ≥18 years with type 1 diabetes across seven diabetes‐care...

article

First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes

Ronnie Aronson, Alexander Abitbol, Katherine S. Tweden

Diabetes, Obesity and Metabolism > 21 > 7 > 1689 - 1694

Aim To investigate the performance of the Eversense XL implantable continuous glucose monitoring (CGM) system through 180 days in a primarily adolescent population with type 1 diabetes (T1D). Materials and methods This prospective, single‐centre, single‐arm, 180‐day study evaluated the effectiveness and safety of the implantable CGM system in Canadian adolescent and adult subjects with T1D. Accuracy...

article

Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial

Caroline M. Apovian, Sajani N. Shah, Bruce M. Wolfe, Sayeed Ikramuddin, more

Obesity Surgery > 2017 > 27 > 1 > 169-176

Background The ReCharge Trial demonstrated that a vagal blocking device (vBloc) is a safe and effective treatment for moderate to severe obesity. This report summarizes 24-month outcomes. Methods Participants with body mass index (BMI) 40 to 45 kg/m², or 35 to 40 kg/m² with at least one comorbid condition were randomized to either vBloc therapy or sham intervention for 12 months. After 12 months,...

article

Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study

Scott A. Shikora, James Toouli, Miguel F Herrera, Bård Kulseng, more

Obesity Surgery > 2016 > 26 > 5 > 1021-1028

Background One-year results of the VBLOC DM2 study found that intermittent vagal blocking (VBLOC therapy) was safe among subjects with obesity and type 2 diabetes mellitus (T2DM) and led to significant weight loss and improvements in glycemic parameters and cardiovascular risk factors. Longer-term data are needed to determine whether the results are sustained. Methods VBLOC DM2 is a prospective,...

article

Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: the ReCharge Study

John M. Morton, Sajani N. Shah, Bruce M. Wolfe, Caroline M. Apovian, more

Obesity Surgery > 2016 > 26 > 5 > 983-989

Background Vagal nerve blockade (vBloc) therapy was shown to be a safe and effective treatment for moderate to severe obesity. This report summarizes the safety and efficacy of vBloc therapy in the prespecified subgroup of patients with moderate obesity. Methods The ReCharge Trial is a double-blind, randomized controlled clinical trial of participants with body mass index (BMI) of 40–45 or 35–40 kg/m...

article

Erratum to: Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study

Scott A. Shikora, James Toouli, Miguel F. Herrera, Bård Kulseng, more

Obesity Surgery > 2016 > 26 > 5 > 1029-1029

article

Reduced Calorie Intake and Weight Loss During Vagal Block (VBLOC Therapy) in Morbidly Obese Patients With Type 2 Diabetes Mellitus

James Toouli, Nicholas H. Wray, Jane Collins, Adele Coles, more

Gastroenterology > 2011 > 140 > 5 Supplement 1 > S-619

article

ET-103 Vagal blocking for the treatment of obesity delivered using the fully implantable maestro rechargeable system: 12 month results

Lilian Kow, Miguel Herrera, Baard Kulseng, Roy Brancatisano, more

Surgery for Obesity and Related Diseases > 2011 > 7 > 3 > 363-364

article

M1270 Correlations Between Enhanced Satiety and Reduced Calorie Intake During Intermittent Vagal Block (VBLOC Therapy) to Treat Obesity

Charles J. Billington, Lilian Kow, Jane Collins, Nicholas H. Wray, more

Gastroenterology > 2009 > 136 > 5 Supplement 1 > A-386

article

M1268 Intermittent Vagal Blocking with An Implantable Device Reduces Maximum Tolerated Volume (MTV) During a Standardized Nutrient Drink Test in Obese Subjects

Miguel F. Herrera, Duane D. Burton, Juan Pablo Pantoja, Sofia Sanchez-Leenheer, more

Gastroenterology > 2009 > 136 > 5 Supplement 1 > A-386

article

P-72: Intermittent vagal blockade with an implantable device improves glycemic control in obese subjects with type 2 diabetes

Miguel F. Herrera, Roy Brancatisano, Ulrich Keller, Baard Kulseng, more

Surgery for Obesity and Related Diseases > 2009 > 5 > 3 Supplement > S48-S49

article

P-81: Intermittent vagal blockade with an implantable device improves blood pressure in obese subjects

James Toouli, Roy Brancatisano, Ulrich Keller, Baard Kulseng, more

Surgery for Obesity and Related Diseases > 2009 > 5 > 3 Supplement > S51-S52

article

Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device

Michael Camilleri, James Toouli, Miguel F. Herrera, Lilian Kow, more

Surgery for Obesity and Related Diseases > 2009 > 5 > 2 > 224-229

A laparoscopically implantable electrical device that intermittently blocks both vagi near the esophagogastric junction led to significant excess weight loss (EWL) in an initial clinical trial in obese patients. The study objective was to optimize therapy algorithms and determine the EWL achieved with a second-generation device at university hospitals in Australia, Norway, and Switzerland.Data acquired...

article

PL-42: Vagal blocking for obesity control (VBLOCTM): Ongoing comparison of weight loss with two generations of an active, implantable medical device

James Toouli, Baard Kulseng, Ulrich Keller, Lilian Kow, more

Surgery for Obesity and Related Diseases > 2008 > 4 > 3 > 305

article

M1255 Intra-Abdominal Vagal Blocking Reduces Calorie Intake, Enhances Satiation and Reduces Hunger During Significant and Sustained Weight Loss in Obese Subjects

James Toouli, Lilian Kow, Jane Collins, Nicholas H. Wray, more

Gastroenterology > 2008 > 134 > 4 Supplement 1 > A-370

article

Transvaginal NOTES Placement of An Implantable Vagal Nerve Blocking Device for Morbid Obesity

Mehran Anvari, Margherita Cadeddu, Michael D. Bierk, Satish Ramadhyani, more

Gastrointestinal Endoscopy > 2008 > 67 > 5 > AB110

article

Vagal Blocking for Obesity Control (VBLOC): Studies of pancreatic and gastric function and safety in a porcine model

Katherine S. Tweden, Michael G. Sarr, Michael Camilleri, Michael L. Kendrick, more

Surgery for Obesity and Related Diseases > 2006 > 2 > 3 > 301-302

article

Description and evaluation of a ventriculo-coronary artery bypass device that provides bi-directional coronary flow

Robert W. Emery, Thierry Carrel, Randall K. Wolf, Marvin J. Slepian, more

European Journal of Cardio-Thoracic Surgery > 2004 > 25 > 1 > 43-50

Objective: The objective of this study was to assess acute patency of a new myocardial revascularization device that connects the left ventricular cavity to a coronary artery (termed ventriculo-coronary artery bypass, VCAB) thereby providing proximal and distal blood flow from the site of the anastomosis. Methods: A device made of expanded polytetrafluoroethylene and low density polyethylene was implanted...

article

Functional myocardial angiogenesis resulting from persistent systolic perfusion

Marvin J. Slepian, Michael J. Mooney, Donald C. Harrison, Robert W. Emery, more

Journal of the American College of Cardiology > 2003 > 41 > 6(S1) > 327-328

article

Ventriculocoronary artery bypass results using a mesh-tipped device in a porcine model

Robert W. Emery, Frazier Eales, Clifford H. Van Meter, Mark B. Knudson, more

The Annals of Thoracic Surgery > 2001 > 72 > 3 > S1004-S1008

Background. In this report we describe the in vivo evaluation of a device and ventriculocoronary artery bypass procedure that creates a permanent transmyocardial channel between the left ventricle and a coronary artery.Methods. The transmyocardial device, an L-shaped titanium tube with a meshed distal tip and an exterior polyester cuff, was implanted from the base of the left ventricle to the proximal...

INFONA - science communication portal

Search results for: Katherine S. Tweden

Clinical use of a 180‐day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes

First assessment of the performance of an implantable continuous glucose monitoring system through 180 days in a primarily adolescent population with type 1 diabetes

Two-Year Outcomes of Vagal Nerve Blocking (vBloc) for the Treatment of Obesity in the ReCharge Trial

Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study

Effect of Vagal Nerve Blockade on Moderate Obesity with an Obesity-Related Comorbid Condition: the ReCharge Study

Erratum to: Intermittent Vagal Nerve Block for Improvements in Obesity, Cardiovascular Risk Factors, and Glycemic Control in Patients with Type 2 Diabetes Mellitus: 2-Year Results of the VBLOC DM2 Study

Reduced Calorie Intake and Weight Loss During Vagal Block (VBLOC Therapy) in Morbidly Obese Patients With Type 2 Diabetes Mellitus

ET-103 Vagal blocking for the treatment of obesity delivered using the fully implantable maestro rechargeable system: 12 month results

M1270 Correlations Between Enhanced Satiety and Reduced Calorie Intake During Intermittent Vagal Block (VBLOC Therapy) to Treat Obesity

M1268 Intermittent Vagal Blocking with An Implantable Device Reduces Maximum Tolerated Volume (MTV) During a Standardized Nutrient Drink Test in Obese Subjects

P-72: Intermittent vagal blockade with an implantable device improves glycemic control in obese subjects with type 2 diabetes

P-81: Intermittent vagal blockade with an implantable device improves blood pressure in obese subjects

Selection of electrical algorithms to treat obesity with intermittent vagal block using an implantable medical device

PL-42: Vagal blocking for obesity control (VBLOCTM): Ongoing comparison of weight loss with two generations of an active, implantable medical device

M1255 Intra-Abdominal Vagal Blocking Reduces Calorie Intake, Enhances Satiation and Reduces Hunger During Significant and Sustained Weight Loss in Obese Subjects

Transvaginal NOTES Placement of An Implantable Vagal Nerve Blocking Device for Morbid Obesity

Vagal Blocking for Obesity Control (VBLOC): Studies of pancreatic and gastric function and safety in a porcine model

Description and evaluation of a ventriculo-coronary artery bypass device that provides bi-directional coronary flow

Functional myocardial angiogenesis resulting from persistent systolic perfusion

Ventriculocoronary artery bypass results using a mesh-tipped device in a porcine model

Filter options

Publication date

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Katherine S. Tweden

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options